MDA-7/interleukin 24 (IL-24) in tumor gene therapy: application of tumor penetrating/homing peptides for improvement of the effects

References

• Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 2005;7(5):457–468.
   PubMed Web of Science ®Google Scholar
• Whitaker EL, Filippov VA, Duerksen-Hughes PJ. Interleukin 24: mechanisms and therapeutic potential of an anti-cancer gene. Cytokine Growth Factor Rev. 2012;23(6):323–331.
   PubMed Web of Science ®Google Scholar
• Jiang H, Lin JJ, Su Z, et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 1995;11(12):2477–2486.
   PubMed Web of Science ®Google Scholar
• Jiang H, Su ZZ, Lin JJ, et al. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Nat Acad Sci. 1996;93(17):9160–9165.
   PubMed Web of Science ®Google Scholar
• Sarkar D, Lebedeva IV, Gupta P, et al. Melanoma differentiation associated gene-7 (mda-7)/IL-24: a ‘magic bullet’ for cancer therapy? Expert Opin Biol Ther. 2007;7(5):577–586.
   PubMed Web of Science ®Google Scholar
• Fisher PB. Is mda-7/IL-24 a “magic bullet” for cancer? Cancer Res. 2005;65(22):10128–10138.
   PubMed Web of Science ®Google Scholar
• Menezes ME, Bhatia S, Bhoopathi P, et al. MDA-7/IL-24: multifunctional cancer killing cytokine. Adv Exp Med Biol. 2014;818:127–153.
   PubMed Web of Science ®Google Scholar
• Sauane M, Su ZZ, Gupta P, et al. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proc Natl Acad Sci U S A. 2008;105(28):9763–9768.
   PubMed Web of Science ®Google Scholar
• Persaud L, De Jesus D, Brannigan O, et al. Mechanism of action and applications of interleukin 24 in immunotherapy. Int J Mol Sci. 2016;17(6):869.
   Web of Science ®Google Scholar
• Ma YF, Ren Y, Wu CJ, et al. Interleukin (IL)-24 transforms the tumor microenvironment and induces anticancer immunity in a murine model of colon cancer. Mol Immunol. 2016;75:11–20.
   PubMed Web of Science ®Google Scholar
• Panneerselvam J, Munshi A, Ramesh R. Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities. J Mol Signal. 2013;8(1):15.
   PubMedGoogle Scholar
• Su ZZ, Lebedeva IV, Sarkar D, et al. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene. 2003;22(8):1164–1180.
   PubMed Web of Science ®Google Scholar
• Miyahara R, Banerjee S, Kawano K, et al. Melanoma differentiation-associated gene-7 (mda-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model. Cancer Gene Ther. 2006;13(8):753–761.
   PubMed Web of Science ®Google Scholar
• Gupta P, Su ZZ, Lebedeva IV, et al. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther. 2006;111(3):596–628.
   PubMed Web of Science ®Google Scholar
• Pradhan AK, Talukdar S, Bhoopathi P, et al. mda-7/IL-24 mediates cancer cell-specific death via regulation of mir-221 and the beclin-1 axis. Cancer Res. 2017;77(4):949–959.
   PubMed Web of Science ®Google Scholar
• Rutz S, Wang X, Ouyang W. The IL-20 subfamily of cytokines–from host defence to tissue homeostasis. Nat Rev Immunol. 2014;14(12):783–795.
   PubMed Web of Science ®Google Scholar
• Sarkar D, Su ZZ, Lebedeva IV, et al. mda-7 (IL-24): signaling and functional roles. Biotechniques. 2002 Oct;Suppl:30–39.
   Web of Science ®Google Scholar
• Russo MA, Paolillo M, Sanchez-Hernandez Y, et al. A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells. Int J Oncol. 2013;42(1):83–92.
   PubMed Web of Science ®Google Scholar
• Conti P, Kempuraj D, Frydas S, et al. IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol Lett. 2003;88(3):171–174.
   PubMed Web of Science ®Google Scholar
• Chada S, Sutton RB, Ekmekcioglu S, et al. MDA-7/IL-24 is a unique cytokine–tumor suppressor in the IL-10 family. Int Immunopharmacol. 2004;4(5):649–667.
   PubMed Web of Science ®Google Scholar
• Hofmann SR, Rosen-Wolff A, Tsokos GC, et al. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol. 2012;143(2):116–127.
   PubMed Web of Science ®Google Scholar
• Stevens L, Htut TM, White D, et al. Involvement of GATA3 in protein kinase C theta-induced Th2 cytokine expression. Eur J Immunol. 2006;36(12):3305–3314.
   PubMed Web of Science ®Google Scholar
• Cunningham CC, Chada S, Merritt JA, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther. 2005;11(1):149–159.
   PubMed Web of Science ®Google Scholar
• Maarof G, Bouchet-Delbos L, Gary-Gouy H, et al. Interleukin-24 inhibits the plasma cell differentiation program in human germinal center B cells. Blood. 2010;115(9):1718–1726.
   PubMed Web of Science ®Google Scholar
• Caudell EG, Mumm JB, Poindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002;168(12):6041–6046.
   PubMed Web of Science ®Google Scholar
• Yu X, Miao J, Xia W, et al. Immunogenicity moderation effect of interleukin-24 on myelogenous leukemia cells. Anticancer Drugs. 2018;29:353‐363.
   Web of Science ®Google Scholar
• Wang M, Tan Z, Zhang R, et al. 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem. 2002;277(9):7341–7347.
   PubMed Web of Science ®Google Scholar
• Wolk K, Kunz S, Asadullah K, et al. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol. 2002;168(11):5397–5402.
   PubMed Web of Science ®Google Scholar
• Seong RK, Choi YK, Shin OS. MDA7/IL-24 is an anti-viral factor that inhibits influenza virus replication. J Microbiol. 2016;54(10):695–700.
   PubMed Web of Science ®Google Scholar
• Jamhiri I, Hosseini SY, Mehrabani D, et al. The pattern of IL24/mda7 and its cognate receptors expression following activation of human hepatic stellate cells. Biomed Rep. 2017;7:173–178.
   PubMed Web of Science ®Google Scholar
• Wang M, Liang P. Interleukin-24 and its receptors. Immunology. 2005;114(2):166–170.
   PubMed Web of Science ®Google Scholar
• Wu B, Huang C, Kato-Maeda M, et al. IL-24 modulates IFN-gamma expression in patients with tuberculosis. Immunol Lett. 2008;117(1):57–62.
   PubMed Web of Science ®Google Scholar
• Ma Y, Chen H, Wang Q, et al. IL-24 protects against Salmonella typhimurium infection by stimulating early neutrophil Th1 cytokine production, which in turn activates CD8+ T cells. Eur J Immunol. 2009;39(12):3357–3368.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li Z, Sheng W, et al. Radiosensitivity by ING4-IL-24 bicistronic adenovirus-mediated gene cotransfer on human breast cancer cells. Cancer Gene Ther. 2013;20(1):38–45.
   PubMed Web of Science ®Google Scholar
• Margue C, Kreis S. IL-24: physiological and supraphysiological effects on normal and malignant cells. Curr Med Chem. 2010;17(29):3318–3326.
   PubMed Web of Science ®Google Scholar
• Park MA, Zhang G, Martin AP, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 2008;7(10):1648–1662.
   PubMed Web of Science ®Google Scholar
• Yang C, Tong Y, Ni W, et al. Inhibition of autophagy induced by overexpression of mda-7/interleukin-24 strongly augments the antileukemia activity in vitro and in vivo. Cancer Gene Ther. 2010;17(2):109–119.
   PubMed Web of Science ®Google Scholar
• Park MA, Walker T, Martin AP, et al. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther. 2009;8(5):1280–1291.
   PubMed Web of Science ®Google Scholar
• Lebedeva IV, Emdad L, Su ZZ, et al. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol. 2007;31(5):985–1007.
   PubMed Web of Science ®Google Scholar
• Bhutia SK, Mukhopadhyay S, Sinha N, et al. Autophagy: cancer’s friend or foe? Adv Cancer Res. 2013;118:61–95.
   PubMed Web of Science ®Google Scholar
• Yacoub A, Park MA, Gupta P, et al. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther. 2008;7(2):297–313.
   PubMed Web of Science ®Google Scholar
• Bhutia SK, Dash R, Das SK, et al. Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res. 2010;70(9):3667–3676.
   PubMed Web of Science ®Google Scholar
• Li J, Yang D, Wang W, et al. Inhibition of autophagy by 3-MA enhances IL-24-induced apoptosis in human oral squamous cell carcinoma cells. J Exp Clin Cancer Res. 2015;34:97.
   PubMed Web of Science ®Google Scholar
• Kreis S, Philippidou D, Margue C, et al. IL-24: a classic cytokine and/or a potential cure for cancer? J Cell Mol Med. 2008;12(6A):2505–2510.
   PubMed Web of Science ®Google Scholar
• Do W, Herrera C, Mighty J, et al. Sigma 1 Receptor plays a prominent role in IL-24-induced cancer-specific apoptosis. Biochem Biophys Res Commun. 2013;439(2):215–220.
   PubMed Web of Science ®Google Scholar
• Kreis S, Philippidou D, Margue C, et al. Recombinant interleukin-24 lacks apoptosis-inducing properties in melanoma cells. PLoS One. 2007;2(12):e1300.
   PubMed Web of Science ®Google Scholar
• Sauane M, Gopalkrishnan RV, Lebedeva I, et al. Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways. J Cell Physiol. 2003;196(2):334–345.
   PubMed Web of Science ®Google Scholar
• Sieger KA, Mhashilkar AM, Stewart A, et al. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther. 2004;9(3):355–367.
   PubMed Web of Science ®Google Scholar
• Liu H, Chen J, Jiang X, et al. Apoptotic signal pathways and regulatory mechanisms of cancer cells induced by IL-24. Wuhan Univ J Nat Sci. 2016;21(6):519–530.
   Google Scholar
• Sarkar D, Su ZZ, Lebedeva IV, et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci U S A. 2002;99(15):10054–10059.
   PubMed Web of Science ®Google Scholar
• Li J, Shi L, Zhang X, et al. Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Cancer Gene Ther. 2010;17(11):771–779.
   PubMed Web of Science ®Google Scholar
• Persaud L, Zhong X, Alvarado G, et al. eIF2alpha phosphorylation mediates IL24-induced apoptosis through inhibition of translation. Mol Cancer Res. 2017;15(8):1117–1124.
   PubMed Web of Science ®Google Scholar
• Iman Jamhiri SZ, Mehrabani D, Khodabandeh Z, et al. Enhancing the apoptotic effect of IL-24/mda-7 on the human hepatic stellate cell through RGD peptide modification. Immunol Invest. 2018 May;47(4):335–350.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang L, Xu W, et al. Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr Cancer Drug Targets. 2013;13(1):92–102.
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mitchell C, Lister A, et al. Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo. Clin Cancer Res. 2003;9(9):3272–3281.
   PubMed Web of Science ®Google Scholar
• Bhutia SK, Das SK, Azab B, et al. Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24. Int J Cancer. 2013;133(11):2726–2736.
   PubMed Web of Science ®Google Scholar
• Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res. 2015;75(1):5–10.
   PubMed Web of Science ®Google Scholar
• Menezes ME, Shen XN, Das SK, et al. MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer. Oncotarget. 2015;6(35):36928–36942.
   PubMedGoogle Scholar
• Sarkar D, Su Z, Park E, et al. A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Ther. 2008;15(5):293–302.
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Hamed HA, et al. MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs. 2010;21(8):725–731.
   PubMed Web of Science ®Google Scholar
• Park MA, Hamed HA, Mitchell C, et al. A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels. Mol Pharmacol. 2011;79(3):368–379.
   PubMed Web of Science ®Google Scholar
• Sauane M, Lebedeva IV, Su ZZ, et al. Melanoma differentiation associated gene-7/interleukin-24 promotes tumor cell-specific apoptosis through both secretory and nonsecretory pathways. Cancer Res. 2004;64(9):2988–2993.
   PubMed Web of Science ®Google Scholar
• Su Z, Emdad L, Sauane M, et al. Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene. 2005;24(51):7552–7566.
   PubMed Web of Science ®Google Scholar
• Fuson KL, Zheng M, Craxton M, et al. Structural mapping of post-translational modifications in human interleukin-24: role of N-linked glycosylation and disulfide bonds in secretion and activity. J Biol Chem. 2009;284(44):30526–30533.
   PubMed Web of Science ®Google Scholar
• Zhang J, Sun A, Xu R, et al. Cell-penetrating and endoplasmic reticulum-locating TAT-IL-24-KDEL fusion protein induces tumor apoptosis. J Cell Physiol. 2016;231(1):84–93.
   PubMed Web of Science ®Google Scholar
• de Figueiredo IR, Freire JM, Flores L, et al. Cell-penetrating peptides: a tool for effective delivery in gene-targeted therapies. IUBMB Life. 2014;66:182–194.
   PubMed Web of Science ®Google Scholar
• Teesalu T, Sugahara KN, Ruoslahti E. Tumor-penetrating peptides. Front Oncol. 2013;3:216.
   PubMedGoogle Scholar
• Krautwald S, Dewitz C, Fandrich F, et al. Inhibition of regulated cell death by cell-penetrating peptides. Cell Mol Life Sci. 2016;73(11–12):2269–2284.
   PubMed Web of Science ®Google Scholar
• Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther. 2010;17(3):295–304.
   PubMed Web of Science ®Google Scholar
• Dinca A, Chien WM, Chin MT. Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease. Int J Mol Sci. 2016;17(2):263.
   PubMed Web of Science ®Google Scholar
• Shin MC, Zhang J, Min KA, et al. Cell-penetrating peptides: achievements and challenges in application for cancer treatment. J Biomed Mater Res A. 2014;102(2):575–587.
   PubMed Web of Science ®Google Scholar
• Rizzuti M, Nizzardo M, Zanetta C, et al. Therapeutic applications of the cell-penetrating HIV-1 Tat peptide. Drug Discov Today. 2015;20(1):76–85.
   PubMed Web of Science ®Google Scholar
• Ziegler A, Nervi P, Durrenberger M, et al. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence. Biochemistry. 2005;44(1):138–148.
   PubMed Web of Science ®Google Scholar
• Drin G, Cottin S, Blanc E, et al. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem. 2003;278(33):31192–31201.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Tsai KC, Kuo PH, et al. A heparan sulfate-binding cell penetrating peptide for tumor targeting and migration inhibition. Biomed Res Int. 2015;2015:237969.
   PubMedGoogle Scholar
• Clayton AH, Atcliffe BW, Howlett GJ, et al. Conformation and orientation of penetratin in phospholipid membranes. J Pept Sci. 2006;12(3):233–238.
   PubMed Web of Science ®Google Scholar
• Derossi D, Calvet S, Trembleau A, et al. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem. 1996;271(30):18188–18193.
   PubMed Web of Science ®Google Scholar
• Pouny Y, Rapaport D, Mor A, et al. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry. 1992;31(49):12416–12423.
   PubMed Web of Science ®Google Scholar
• Trabulo S, Cardoso AL, Mano M, et al. Cell-penetrating peptides-mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals (Basel). 2010;3(4):961–993.
   PubMedGoogle Scholar
• Zhang D, Wang J, Xu D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J Control Release. 2016;229:130–139.
   PubMed Web of Science ®Google Scholar
• Zahid M, Robbins PD. Cell-type specific penetrating peptides: therapeutic promises and challenges. Molecules. 2015;20(7):13055–13070.
   PubMed Web of Science ®Google Scholar
• Grifman M, Trepel M, Speece P, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther. 2001;3(6):964–975.
   PubMed Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279(5349):377–380.
   PubMed Web of Science ®Google Scholar
• Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology. 1995;13(3):265–270.
   PubMedGoogle Scholar
• Moore NM, Barbour TR, Sakiyama-Elbert SE. Synthesis and characterization of four-arm poly(ethylene glycol)-based gene delivery vehicles coupled to integrin and DNA-binding peptides. Mol Pharm. 2008;5(1):140–150.
   PubMedGoogle Scholar
• Simon-Gracia L, Hunt H, Scodeller P, et al. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. Biomaterials. 2016;104:247–257.
   PubMed Web of Science ®Google Scholar
• Corti A, Curnis F, Rossoni G, et al. Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example. BioDrugs. 2013;27(6):591–603.
   PubMed Web of Science ®Google Scholar
• Johansson A, Hamzah J, Payne CJ, et al. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A. 2012;109(20):7841–7846.
   PubMed Web of Science ®Google Scholar
• Yao VJ, Ozawa MG, Trepel M, et al. Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. Am J Pathol. 2005;166(2):625–636.
   PubMed Web of Science ®Google Scholar
• Duggineni S, Mitra S, Lamberto I, et al. Design and synthesis of potent bivalent peptide agonists targeting the EphA2 receptor. ACS Med Chem Lett. 2013;4(3):344–348.
   Web of Science ®Google Scholar
• Lu L, Qi H, Zhu J, et al. Vascular-homing peptides for cancer therapy. Biomed Pharmacother. 2017;92:187–195.
   PubMed Web of Science ®Google Scholar
• Boohaker RJ, Lee MW, Vishnubhotla P, et al. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem. 2012;19(22):3794–3804.
   PubMed Web of Science ®Google Scholar
• Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids. 2012;2012:1–13.
   Google Scholar
• Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60(3):722–727.
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000;18(11):1185–1190.
   PubMed Web of Science ®Google Scholar
• Curnis F, Gasparri A, Sacchi A, et al. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res. 2004;64(2):565–571.
   PubMed Web of Science ®Google Scholar
• Bertilaccio MT, Grioni M, Sutherland BW, et al. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate. 2008;68(10):1105–1115.
   PubMed Web of Science ®Google Scholar
• Dickerson EB, Akhtar N, Steinberg H, et al. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res. 2004;2(12):663–673.
   PubMed Web of Science ®Google Scholar
• Curnis F, Gasparri A, Sacchi A, et al. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 2005;65(7):2906–2913.
   PubMed Web of Science ®Google Scholar
• Chen S, Huang Q, Liu J, et al. A targeted IL-15 fusion protein with potent anti-tumor activity. Cancer Biol Ther. 2015;16(9):1415–1421.
   PubMed Web of Science ®Google Scholar
• Curnis F, Fiocchi M, Sacchi A, et al. NGR-tagged nano-gold: a new CD13-selective carrier for cytokine delivery to tumors. Nano Res. 2016;9(5):1393–1408.
   PubMed Web of Science ®Google Scholar
• Gregorc V, Citterio G, Vitali G, et al. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer. 2010;46(1):198–206.
   PubMed Web of Science ®Google Scholar
• Alghisi GC, Ponsonnet L, Ruegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One. 2009;4(2):e4449.
   PubMed Web of Science ®Google Scholar
• Hariharan S, Gustafson D, Holden S, et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol. 2007;18(8):1400–1407.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Gorlia T, Erridge S, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. J Clin Oncol. 2013;31(18_suppl):LBA2009.
   Web of Science ®Google Scholar
• Ma Q, Jin B, Zhang Y, et al. Secreted recombinant human IL-24 protein inhibits the proliferation of esophageal squamous cell carcinoma Eca-109 cells in vitro and in vivo. Oncol Rep. 2016;35(5):2681–2690.
   PubMed Web of Science ®Google Scholar
• Rousseaux CG, Greene SF. Sigma receptors [sigmaRs]: biology in normal and diseased states. J Recept Signal Transduct Res. 2016;36(4):327–388.
   PubMed Web of Science ®Google Scholar
• Xiao B, Li W, Yang J, et al. RGD-IL-24, a novel tumor-targeted fusion cytokine: expression, purification and functional evaluation. Mol Biotechnol. 2009;41(2):138–144.
   PubMed Web of Science ®Google Scholar
• Zhang BF, Liu JJ, Pei DS, et al. Potent antitumor effect elicited by RGD-mda-7, an mda-7/IL-24 mutant, via targeting the integrin receptor of tumor cells. Cancer Biother Radiopharm. 2011;26(5):647–655.
   PubMed Web of Science ®Google Scholar
• Bina S, Shenavar F, Khodadad M, et al. Impact of RGD peptide tethering to IL24/mda-7 (Melanoma Differentiation Associated Gene-7) on apoptosis induction in hepatocellular carcinoma cells. Asian Pac J Cancer Prev. 2015;16(14):6073–6080.
   PubMedGoogle Scholar
• Hosseini E, Hosseini SY, Hashempour T, et al. Effect of RGD coupled MDA-7/IL-24 on apoptosis induction in a hepatocellular carcinoma cell line. Mol Med Rep. 2017;15(1):495–501.
   PubMed Web of Science ®Google Scholar
• Khodadad M, Hosseini SY, Shenavar F, et al. Construction of expressing vectors including melanoma differentiation-associated gene-7 (mda-7) fused with the RGD sequences for better tumor targeting. Iran J Basic Med Sci. 2015;18(8):780–787.
   PubMed Web of Science ®Google Scholar
• Bina S, Hosseini SY, Shenavar F, et al. The effect of RGD/NGR peptide modification of melanoma differentiation-associated gene-7/interleukin-24 on its receptor attachment, an in silico analysis. Cancer Biother Radiopharm. 2017;32(6):205–214.
   PubMed Web of Science ®Google Scholar